{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOSAPREPITANT+%28Emend%29",
    "query": {
      "intervention": "FOSAPREPITANT (Emend)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOSAPREPITANT+%28Emend%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T02:00:28.114Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01504711",
      "title": "Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Nausea Post Chemotherapy"
      ],
      "interventions": [
        {
          "name": "fosaprepitant dimeglumine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Philip",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-06",
      "completion_date": "2020-09-03",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01504711"
    },
    {
      "nct_id": "NCT02550119",
      "title": "Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Digestive System Neoplasm",
        "Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Dolasetron Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2006-04-19",
      "completion_date": "2010-04-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02550119"
    },
    {
      "nct_id": "NCT00659945",
      "title": "Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Aprepitant plus Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron plus placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2008-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2013-02-06",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659945"
    },
    {
      "nct_id": "NCT01851369",
      "title": "TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphomas",
        "Solid Tumors",
        "NSCLC",
        "Metastatic Colon Carcinoma",
        "Granulosa Cell Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TRC102",
          "type": "DRUG"
        },
        {
          "name": "CT scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Lomotil",
          "type": "OTHER"
        },
        {
          "name": "Prochlorperazine",
          "type": "OTHER"
        },
        {
          "name": "Metoclopramide",
          "type": "OTHER"
        },
        {
          "name": "5-HT3 antagonist",
          "type": "OTHER"
        },
        {
          "name": "Aprepitant",
          "type": "OTHER"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 93,
      "start_date": "2013-07-12",
      "completion_date": "2023-08-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01851369"
    },
    {
      "nct_id": "NCT01534637",
      "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Nausea",
        "Vomiting",
        "Stage II Pancreatic Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "aprepitant",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "nausea and vomiting therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2006-08",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01534637"
    },
    {
      "nct_id": "NCT00248547",
      "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "aprepitant",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "ondansetron",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-05",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248547"
    },
    {
      "nct_id": "NCT00314743",
      "title": "Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Nausea",
        "Vomiting"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2005-10",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-24",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314743"
    },
    {
      "nct_id": "NCT02130687",
      "title": "Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Mixed Meal Test (MMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 106,
      "start_date": "2014-06",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130687"
    },
    {
      "nct_id": "NCT01625455",
      "title": "Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sezary Syndrome",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 7,
      "start_date": "2012-02",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01625455"
    },
    {
      "nct_id": "NCT00699894",
      "title": "Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postoperative Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "aprepitant 40 mg",
          "type": "DRUG"
        },
        {
          "name": "ondansetron 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "15 Years to 25 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2008-06",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2013-08-12",
      "last_synced_at": "2026-09-03T02:00:28.114Z",
      "location_count": 1,
      "location_summary": "New Hyde Park, New York",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00699894"
    }
  ]
}